Myeloid-derived suppressor cells function as novel osteoclast progenitors enhancing bone loss in breast cancer

Cancer Research

Volumn 73, Issue 2, 2013, Pages 672-682

  Sawant, Anandi ^a   Deshane, Jessy ^b   Jules, Joel ^a   Lee, Carnella M ^a   Harris, Brittney A ^a   Feng, Xu ^a   Ponnazhagan, Selvarangan ^a  

^a University of Alabama at Birmingham   (United States)

^b University of Alabama at Birmingham   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NITRIC OXIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE DESTRUCTION; BONE MARROW CELL; BONE METASTASIS; BREAST CANCER; CANCER GROWTH; CELL DIFFERENTIATION; CELL INTERACTION; CONTROLLED STUDY; FEMALE; IN VITRO STUDY; IN VIVO STUDY; MACROPHAGE; MOUSE; MYELOID DERIVED SUPPRESSOR CELL; NONHUMAN; OSTEOCLAST; OSTEOLYSIS; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; STEM CELL; TUMOR MICROENVIRONMENT;

ANIMALS; BONE NEOPLASMS; BONE RESORPTION; BREAST NEOPLASMS; CELL DIFFERENTIATION; CELL LINE, TUMOR; FEMALE; HUMANS; MICE; MICE, INBRED BALB C; MYELOID CELLS; NITRIC OXIDE; OSTEOCLASTS; OSTEOLYSIS;

EID: 84872554724     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-12-2202     Document Type: Article

References (47)

1. Gabrilovich DI, Ostrand-Rosenberg S, Bronte V. Coordinated regulation of myeloid cells by tumours. Nat Rev Immunol 2012;12: 253-268.
2. Ostrand-Rosenberg SSP. Myeloid-derived suppressor cells: linking inflammation and cancer. J Immunol 2009;182: 4499-506.
3. Nagaraj S, Gabrilovich DI. Myeloid-derived suppressor cells in human cancer. Cancer J 2010;16: 348-53.
4. Ostrand-Rosenberg S. Myeloid-derived suppressor cells: more mechanisms for inhibiting antitumor immunity. Cancer Immunol Immunother 2010;59: 1593-600.
5. Tadmor T, Attias D, Polliack A. Myeloid-derived suppressor cells-their role in haemato-oncological malignancies and other cancers and possible implications for therapy. Br J Haematol 2011;153: 557-67.
6. Morales JK, Kmieciak M, Graham L, Feldmesser M, Bear HD, Manjili M H. Adoptive transfer of HER2/neu-specific T cells expanded with alternating gamma chain cytokines mediate tumor regression when combined with the depletion of myeloid- derived suppressor cells. Cancer Immunol Immunother 2009; 58: 941-53.
7. Young MR, Young ME, Wepsic HT. Effect of prostaglandin E2-producing nonmetastatic Lewis lung carcinoma cells on the migration of prostaglandin E2-responsive metastatic Lewis lung carcinoma cells. Cancer Res 1987;47: 3679-83.
8. Melani C, Sangaletti S, Barazzetta FM, Werb Z, Colombo MP. Aminobiphosphonate- mediated MMP-9 inhibition breaks the tumor-bone marrow axis responsible for myeloid-derived suppressor cell expansion and macrophage infiltration in tumor stroma. Cancer Res 2007; 67: 11438-46.
9. Coleman RE. Metastatic bone disease: clinical features, pathophysiology and treatment strategies. Cancer Treat Rev 2001;27: 165-76.
10. Coleman RE, Rubens RD. 3(Amino-1,1-hydroxypropylidene) bisphosphonate (APD) for hypercalcaemia of breast cancer. Br J Cancer 1987;56: 465-9.
11. Roodman GD. Mechanisms of bone metastasis. N Engl J Med 2004;350: 1655-64.
12. Udagawa N, Takahashi N, Akatsu T, Tanaka H, Sasaki T, Nishihara T, et al. Origin of osteoclasts: mature monocytes and macrophages are capable of differentiating into osteoclasts under a suitable microenvironment prepared by bone marrow-derived stromal cells. Proc Natl Acad Sci U S A 1990;87: 7260-64.
13. Gabrilovich DI, Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol 2009;9: 162-74.
14. Jules J, Shi Z, Liu J, Xu D, Wang S, Feng X. Receptor activator of NF- {kappa}B (RANK) cytoplasmic IVVY535-538 motif plays an essential role in tumor necrosis factor-{alpha} (TNF)-mediated osteoclastogenesis. J Biol Chem 2010;285: 37427-35.
15. Jia W, Jackson-Cook C, Graf MR. Tumor-infiltrating, myeloid-derived suppressor cells inhibit T cell activity by nitric oxide production in an intracranial rat glioma + vaccination model. J Neuroimmunol 2010; 223: 20-30.
16. Erlebacher A, Derynck R. Increased expression of TGF-beta 2 in osteoblasts results in an osteoporosis-like phenotype. J Cell Biol 1996;132: 195-210.
17. Sinha P, Clements VK, Bunt SK, Albelda SM, Ostrand-Rosenberg S. Cross-talk between myeloid-derived suppressor cells and macrophages subverts tumor immunity toward a type 2 response. J Immunol 2007;179: 977-83.
18. Suzuki E, Kapoor V, Jassar AS, Kaiser LR, Albelda SM. Gemcitabine selectively eliminates splenic Gr-1+/CD11b+ myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity. Clin Cancer Res 2005;11: 6713-21.
19. Parfitt AM, Simon LS, Villanueva AR, Krane SM. Procollagen type I carboxy-terminal extension peptide in serum as a marker of collagen biosynthesis in bone. Correlation with iliac bone formation rates and comparison with total alkaline phosphatase. J Bone Miner Res 1987;2: 427-36.
20. Anderson JT, Zeng M, Li Q, Stapley R, Moore DR 2nd, Chenna B, et al. Elevated levels of NO are localized to distal airways in asthma. Free Radic Biol Med 2011;50: 1679-88.
21. Deshane J, Zmijewski JW, Luther R, Gaggar A, Deshane R, Lai JF, et al. Free radical-producing myeloid-derived regulatory cells: potent activators and suppressors of lung inflammation and airway hyperresponsiveness. Mucosal Immunol 2011;4: 503-18.
22. Ashley JW, Shi Z, Zhao H, Li X, Kesterson RA, Feng X. Genetic ablation of CD68 results in mice with increased bone and dysfunctional osteoclasts. Plos One 2011;6:e25838.
23. Hsu YC, Cheng CP, Chang DM. Plectranthus amboinicus attenuates inflammatory bone erosion in mice with collagen-induced arthritis by downregulation of RANKL-induced NFATc1 expression. J Rheumatol 2011;38: 1844-57.
24. Youn JIGD. The biology of myeloid-derived suppressor cells: the blessing and the curse of morphological and functional heterogeneity. Eur J Immunol 2010;40: 2969-75.
25. Peranzoni EZS, Marigo I, Dolcetti L, Zanovello P, Mandruzzato S, Bronte V. Myeloid-derived suppressor cell heterogeneity and subset definition. Curr Opinion Immunol 2010;22: 238-44.
26. Corzo CA, Condamine T, Lu L, Cotter MJ, Youn JI, Cheng P, et al. HIF- 1alpha regulates function and differentiation of myeloid-derived suppressor cells in the tumor microenvironment. J Exp Med 2010;207: 2439-53.
27. Kasuno K, Takabuchi S, Fukuda K, Kizaka-Kondoh S, Yodoi J, Adachi T, et al. Nitric oxide induces hypoxia-inducible factor 1 activation that is dependent on MAPK and phosphatidylinositol 3-kinase signaling. J Biol Chem 2004;279: 2550-8.
28. Hiraga T, Kizaka-Kondoh S, Hirota K, Hiraoka M, Yoneda T. Hypoxia and hypoxia-inducible factor-1 expression enhance osteolytic bone metastases of breast cancer. Cancer Res 2007; 67: 4157-63.
29. Knowles HJ, Athanasou NA. Acute hypoxia and osteoclast activity: a balance between enhanced resorption and increased apoptosis. J Pathol 2009;218: 256-64.
30. Knowles HJ, Cleton-Jansen AM, Korsching E, Athanasou NA. Hypoxia- inducible factor regulates osteoclast-mediated bone resorption: role of angiopoietin-like 4. Faseb J 2010;24: 4648-59.
31. Sheta EA, Trout H, Gildea JJ, Harding MA, Theodorescu D. Cell density mediated pericellular hypoxia leads to induction ofHIF-1alpha via nitric oxide and Ras/MAP kinase mediated signaling pathways. Oncogene 2001;20: 7624-34.
32. Nilforoushan DGA, Glogauer M, Manolson MF. Nitric oxide enhances osteoclastogenesis possibly by mediating cell fusion. Nitric Oxide 2009;21: 27-36.
33. Herrera BSM-PR, Maia-Dantas A, Campi P, Spolidorio LC, Costa SK, Van Dyke TE, et al. iNOS-derived nitric oxide stimulates osteoclast activity and alveolar bone loss in ligature-induced periodontitis in rats. J Periodontol 2011;82: 1608-15.
34. Gyurko RSH, Battaglino RA, Boustany G, Gibson FC 3rd, Genco CA, Stashenko P, et al. Inducible nitric oxide synthase mediates bone development and P. gingivalis-induced alveolar bone loss. Bone 2005; 36: 472-9.
35. Blavier L, Delaisse JM. Matrix metalloproteinases are obligatory for the migration of preosteoclasts to the developing marrow cavity of primitive long bones. J Cell Sci 1995;108 (Pt 12): 3649-59.
36. Sato T, Foged NT, Delaisse JM. The migration of purified osteoclasts through collagen is inhibited by matrix metalloproteinase inhibitors. J Bone Miner Res 1998;13: 59-66.
37. Das S, Samant RS, Shevde LA. Hedgehog signaling induced by breast cancer cells promotes osteoclastogenesis and osteolysis. J Biol Chem 2011;286: 9612-22.
38. Mi Z, Guo H, Wai PY, Gao C, Wei J, Kuo PC. Differential osteopontin expression in phenotypically distinct subclones of murine breast cancer cells mediates metastatic behavior. J Biol Chem 2004;279: 46659-67.
39. Soria G, Ben-Baruch A. The inflammatory chemokines CCL2 and CCL5 in breast cancer. Cancer Lett 2008;267: 271-85.
40. Skuljec J, Sun H, Pul R, Benardais K, Ragancokova D, Moharregh- Khiabani D, et al. CCL5 induces a pro-inflammatory profile in microglia in vitro. Cell Immunol 2011;270: 164-71.
41. Huang B, Lei Z, Zhao J, Gong W, Liu J, Chen Z, et al. CCL2/CCR2 pathway mediates recruitment of myeloid suppressor cells to cancers. Cancer Lett 2007;252: 86-92.
42. Loesch D, Asmar L, McIntyre K, Doane L, Monticelli M, Paul D, et al. Phase II trial of gemcitabine/carboplatin (plus trastuzumab in HER2- positive disease) in patients with metastatic breast cancer. Clin Breast Cancer 2008;8: 178-86.
43. Brito LG, de Andrade JM, Lins-Almeida T, Zola FE, Pinheiro MN, Marana HR, et al. Safety and efficacy of gemcitabine plus cisplatin combination in pretreated metastatic breast cancer patients. Med Oncol 2012;29: 33-8.
44. Chun SH, Lee JE, Park MH, Kang JH, Kim YK, Wang YP, et al. Gemcitabine plus platinum combination chemotherapy for elderly patients with advanced non-small cell lung cancer: a retrospective analysis. Cancer Res Treat 2011;43: 217-24.
45. Le HK, Graham L, Cha E, Morales JK, Manjili MH, Bear HD. Gemcitabine directly inhibits myeloid derived suppressor cells in BALB/c mice bearing 4T1 mammary carcinoma and augments expansion of T cells from tumor-bearing mice. Int Immunopharmacol 2009;9: 900-9.
46. Gnant M, Dubsky P, Hadji P. Bisphosphonates: prevention of bone metastases in breast cancer. Recent Results Cancer Res 2012;192: 65-91.
47. Monsees GM, Malone KE, Tang MT, Newcomb PA, Li CI. Bisphosphonate use after estrogen receptor-positive breast cancer and risk of contralateral breast cancer. J Natl Cancer Inst 2011;103: 1752-60.